Advances in Cell and Gene Therapy

About this Journal

Aims and scope

Advances in Cell and Gene Therapy is an international journal publishing original, high-quality, peer-reviewed articles which cover basic and clinical research relating to advances in cell, gene, and immune therapies and their use in the treatment of a wide range of diseases, including cancer, genetic and immune diseases, and others. 

The topics the journal covers include cell, gene and immune therapies in children and adults with a wide range of disorders, including cancers, genetic and immune diseases, and others. All articles include a section or feature detailing the current and future clinical implications of the research.

Among the extensive and provocative reviews, Advances in Cell and Gene Therapy provides a forum for presenting original research articles and sharing ideas for innovation, as well as disseminating knowledge of primary clinical relevance to advance patient care.

    The Wiley Hindawi Partnership

    This journal is published by Hindawi as part of a publishing collaboration with John Wiley & Sons, Inc. It is a fully Open Access journal produced under the Hindawi and Wiley brands.

    Bibliographic information

    ISSN: 2573-8461 (Online)

    DOI: 10.1155/acgt

    Archival content

    Content published prior to 2022 is hosted on the Wiley Online Library.

      Open Access

      Advances in Cell and Gene Therapy is an open access journal. All articles are immediately available to read and reuse upon publication. More information about our Open Access policy can be found on our copyright page.


        Editorial enquiries should be directed to

        General enquiries should be directed to


          Advances in Cell and Gene Therapy
          Publishing Collaboration
          More info
          Wiley Hindawi logo
           Journal metrics

          Metrics will be available once more articles are published.


          Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.